Parasitemia

Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges

Retrieved on: 
Tuesday, July 11, 2023

Providence, RI, July 11, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, announced today that it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan Africa while recognizing newly emerging global malaria challenges.

Key Points: 
  • Based on discoveries by Scientific Co-founder, Jonathan Kurtis, MD, PhD, Ocean Biomedical is working on a multivalent mRNA-based malaria vaccine with potential to target several stages in the malaria cycle.
  • Additionally, the company has discovered a new therapeutic approach with the potential to launch a whole new class of anti-malarials.
  • Multiple U.S. and global patents are held by Ocean Biomedical for both the vaccine and therapeutic approaches.
  • Ocean Biomedical’s novel malaria vaccine program is based on groundbreaking discoveries by Dr. Kurtis that have revealed new insights into how malaria parasites maintain homeostasis in their hosts.

Hesperos Scientists Publish a New Study in Scientific Reports Titled: "Development of a Human Malaria-on-a-Chip Disease Model for Drug Efficacy and Off-Target Toxicity Evaluation"

Retrieved on: 
Wednesday, July 5, 2023

In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.

Key Points: 
  • In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.
  • Through their efforts they developed a human-based model to study the disease pathology and therapeutic effects in a pre-clinical platform.
  • This microfluidic platform connects human liver, spleen, and endothelium with recirculating human erythrocytes in a controlled, self-contained platform.
  • This new approach to the evaluation of Plasmodium falciparum and anti-malarial therapeutics is executed in a realistic human model.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis

Retrieved on: 
Thursday, June 8, 2023

Providence, RI, June 08, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD has been granted a new patent for his malaria vaccine discoveries that may be used to interdict the parasite at multiple stages in the malaria cycle. This extends patent protection for Dr. Kurtis’ novel discoveries that have defined the powerful roles of PfGARP and PfCDPK-5 in controlling the malaria parasite’s ability to aggressively multiply within its human host.

Key Points: 
  • This extends patent protection for Dr. Kurtis’ novel discoveries that have defined the powerful roles of PfGARP and PfCDPK-5 in controlling the malaria parasite’s ability to aggressively multiply within its human host.
  • This patent adds to Ocean Biomedical’s global patent portfolio for discoveries with potential to impact major unmet medical needs in infectious disease, oncology , and fibrosis .
  • Ocean Biomedical is working to optimize the formulation of this vaccine prior to IND submission and first-in-humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis

Retrieved on: 
Thursday, April 13, 2023

A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.

Key Points: 
  • A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.
  • Ocean Biomedical anticipates that a patent will be issued by the USPTO from Dr. Kurtis’ application in the coming months.
  • “With the rising resistance to artemisinin-based drugs in sub-Saharan Africa, it is imperative that we get new malaria therapeutics into the drug development pipeline,” said Elizabeth Ng, Ocean Biomedical’s CEO.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.

Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria

Retrieved on: 
Tuesday, March 21, 2023

Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.

Key Points: 
  • Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.
  • Dr. Elias is Ocean Biomedical’s other Scientific Co-founder and Dean Emeritus of Medicine and Biological Sciences at Brown University.
  • This differential screening technique has led to the discovery of three key targets that are being formulated into a highly effective malaria vaccine candidate being advanced by Dr. Kurtis and Ocean Biomedical.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target

Retrieved on: 
Tuesday, February 28, 2023

Providence, RI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder and member of the board of directors Dr. Jonathan Kurtis, MD, PhD, has been awarded a new patent for his discovery related to malaria, a third parasite target called PfCDPK-5 that can potentially be used to interdict the parasite at multiple stages in the malaria cycle. This discovery builds on Dr. Kurtis’ previous discoveries that have defined the powerful roles of PfGARP and PfSEA in controlling the malaria parasite’s ability to replicate and grow within its human host. The latest patent is for the discovery that demonstrates the role of antibodies to PfCDPK-5 in preventing merozoites from escaping infected red blood cells and thus attenuates parasite multiplication in the bloodstream.

Key Points: 
  • If combined with the new target PfCDPK-5 and PfSEA, the vaccine has the potential to shut down the parasite at multiple points in its cycle.
  • In coming months, Dr. Kurtis will work to optimize the formulation of his vaccine prior to IND submission and first in humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.
  • “Falciparum malaria is a leading cause of death in children world-wide and our global malaria treatment strategy relies almost exclusively on artemisinin-based drugs.

Novel Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis, unveiling the potential for a new class of Antimalarial Drugs.

Retrieved on: 
Tuesday, November 1, 2022

Providence, RI and New York, NY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today that Scientific Co-founder, Dr. Jake Kurtis, will present groundbreaking research discoveries at this week’s Annual Meeting of The American Society of Tropical Medicine and Hygiene. These discoveries have the potential to launch a whole new class of antimalarial drugs, and come at time when current artemisinin-based treatments are beginning to lose efficacy.

Key Points: 
  • Along with the related vaccine program, this small molecule drug program will be a key focus of Ocean Biomedicals development pipeline in 2023.
  • Malaria caused by infection with Plasmodium parasites is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals last year.
  • Suren Ajjarapu, Chairman and CEO of Aesther, commented, Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today.
  • Such information with respect to Ocean Biomedical's directors and executive officers will also be included in the proxy statement.

Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.

Retrieved on: 
Thursday, September 22, 2022

Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) recently announced business combination, once closed, will further Ocean Biomedical’s work on the discovery of a whole new class of antimalarial drugs which target PfGARP and kill malaria parasites.

Key Points: 
  • Ocean Biomedical and Aesther Healthcare are proud to add this significant program to our pipeline.
  • Suren Ajjarapu, Chairman and CEO of Aesther, commented, Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today.
  • Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical.
  • Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

Sysmex America Introduces First Hematology Analyzer for Malaria Detection: XN-30™ Research Use Only Automated Hematology Analyzer

Retrieved on: 
Friday, October 1, 2021

"The XN-30 Research Use Only Automated Hematology Analyzer delivers workflow efficiency and enhanced staff productivity to research labs currently performing manual microscopy for detection of malaria or relying on rapid diagnostic tests to screen symptomatic patients," said Andy Hay, chief executive officer of Sysmex America.

Key Points: 
  • "The XN-30 Research Use Only Automated Hematology Analyzer delivers workflow efficiency and enhanced staff productivity to research labs currently performing manual microscopy for detection of malaria or relying on rapid diagnostic tests to screen symptomatic patients," said Andy Hay, chief executive officer of Sysmex America.
  • Three levels of quality control material ensure analyzer performance and provide a new level of confidence in the results produced.
  • Sysmex America is lighting the way to better health with diagnostic solutions that transform the future of healthcare and contribute to healthier lives.
  • Its innovative hematology, urinalysis, information systems and flow cytometry testing technology are reshaping the world of diagnostics.